Angiotech showcases its Hemostream(TM) Dialysis Catheter at the Society of Interventional Radiology (SIR) Annual Meeting
13 März 2008 - 9:35PM
PR Newswire (US)
An Innovative Chronic Dialysis Catheter With Patented Triple
Arterial Lumen Design VANCOUVER, March 13 /PRNewswire-FirstCall/ --
Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP)
today announced that it will introduce and exhibit its innovative
HemoStream(TM) chronic dialysis catheter at the 2008 Society of
Interventional Radiology (SIR) Annual Scientific Meeting to be held
in Washington, DC from March 15-18, 2008. "It's exciting to
participate at SIR and showcase the addition of another
'best-in-class' device offered by Angiotech. We also anticipate
that the HemoStream(TM) could be a great candidate for our
combination drug-device technologies, such as Angiotech's
innovative 5-FU anti-infective platform," said George Leondis,
General Manager, Angiotech Interventional. Incidences of End Stage
Renal Disease (ESRD) requiring dialysis are a rapidly growing
challenge in healthcare worldwide. When kidneys fail, function of
the kidneys can be partially replaced using a process called
hemodialysis. Hemodialysis involves drawing blood out of the body,
filtering it through a large machine and then returning filtered
blood back to the body. Chronic dialysis catheters, such as
HemoStream(TM), are used as long term vascular access for
hemodialysis. HemoStream may also be used as a temporary access
while more permanent options mature or become ready for use, such
as a surgically created AV fistula. A dialysis catheter, such as
HemoStream(TM), is used for vascular access and is a vital
connection between the patient and the hemodialysis unit. When
kidneys fail, the function of the kidneys can be partially replaced
using a process called hemodialysis. Hemodialysis involves drawing
blood out of the body, filtering it through a large machine that
draws off the impurities and then returning the filtered blood to
the body. When patients are placed on hemodialysis, they will
require placement of a catheter into a large vein which is then
connected to a hemodialysis machine. Some of the potential benefits
of the HemoStream(TM) catheter include: - Patented Triple Arterial
Lumen Design: Ensures functional flow rates in the event that two
lumens become completely occluded. - Transition: Provides
atraumatic over-the-wire insertion without the need for a peel-away
sheath. - 360 degree Arterial Tip Configuration: Eliminates
catheter "side- walling" against vessel. In April 2007, Angiotech
entered into an agreement with Rex Medical, LP, which granted
Angiotech an exclusive license to market and distribute the
HemoStream(TM) catheter worldwide. The U.S. Food and Drug
Administration (FDA) has given clearance to begin marketing the
HemoStream(TM) chronic dialysis catheter in the United States.
Angiotech will be exhibiting in Booth #233 at the 33rd Annual
Meeting of the Society of Interventional Radiologists to be held
March 15-18th, 2008 in Washington, D.C. More information about the
meeting can be found on the Society of Interventional Radiology
website at:
http://www.sirweb.org/annualMeeting/annualMeetingHome.shtml About
Angiotech Angiotech Pharmaceuticals, Inc. is a global specialty
pharmaceutical and medical device company with over 1,600 dedicated
employees. Angiotech discovers, develops and markets innovative
treatment solutions for diseases or complications associated with
medical device implants, surgical interventions and acute injury.
To find out more about Angiotech
(NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP), please visit
http://www.angiotech.com/. FORWARD-LOOKING STATEMENTS: Statements
contained in this press release that are not based on historical
fact, including without limitation statements containing the words
"believes," "may," "plans," "will," "estimate," "continue,"
"anticipates," "intends," "expects" and similar expressions,
constitute "forward-looking statements" within the meaning of the
U.S. Private Securities Litigation Reform Act of 1995 and
constitute "forward-looking information" within the meaning of
applicable Canadian securities laws. All such statements are made
pursuant to the "safe harbor" provisions of applicable securities
legislation. Forward-looking statements may involve, but are not
limited to, comments with respect to our strategies or future
actions, our targets, expectations for our financial condition and
the results of, or outlook for, our operations, research
development and product and drug development. Such forward-looking
statements involve known and unknown risks, uncertainties and other
factors that may cause the actual results, events or developments
to be materially different from any future results, events or
developments expressed or implied by such forward-looking
statements. Many such risks, uncertainties and other factors are
taken into account as part of our assumptions underlying these
forward-looking statements and include, among others, the
following: general economic and business conditions, both
nationally and in the regions in which we operate; market demand;
technological changes that could impact our existing products or
our ability to develop and commercialize future products;
competition; existing governmental regulations and changes in, or
the failure to comply with, governmental regulations; adverse
results or unexpected delays in drug discovery and clinical
development processes; decisions, and the timing of decisions, made
by health regulatory agencies regarding approval of our technology
and products; the requirement for substantial funding to conduct
research and development and to expand commercialization activities
or consummate acquisitions; the accuracy of our estimations of the
size of the market, and the potential market, for our products in
specific disease areas; sales numbers and future guidance publicly
provided by Boston Scientific Corporation regarding sales of their
paclitaxel-eluting coronary stent products; and any other factors
that may affect performance. In addition, our business is subject
to certain operating risks that may cause the actual results
expressed or implied by the forward-looking statements in this
report to differ materially from our actual results. These
operating risks include: our ability to attract and retain
qualified personnel; our ability to successfully complete
preclinical and clinical development of our products; changes in
business strategy or development plans; our failure to obtain
patent protection for discoveries; loss of patent protection
resulting from third party challenges to our patents;
commercialization limitations imposed by patents owned or
controlled by third parties; our ability to obtain rights to
technology from licensors; liability for patent claims and other
claims asserted against us; our ability to obtain and enforce
timely patent and other intellectual property protection for our
technology and products; the ability to enter into, and to
maintain, corporate alliances relating to the development and
commercialization of our technology and products; market acceptance
of our technology and products; our ability to successfully
manufacture, market and sell our products; the ability of Boston
Scientific Corporation to successfully manufacture, market and sell
their paclitaxel-eluting coronary stent products; the continued
availability of capital to finance our activities; our ability to
achieve the financial benefits expected as a result of the
acquisition of American Medical Instruments Holdings, Inc. ("AMI");
and any other factors referenced in our annual information form and
other filings with the applicable Canadian securities regulatory
authorities or the SEC. Given these uncertainties, assumptions and
risk factors, readers are cautioned not to place undue reliance on
such forward-looking statements. We disclaim any obligation to
update any such factors or to publicly announce the result of any
revisions to any of the forward-looking statements contained in
this press release to reflect future results, events or
developments. (TM)HemoStream is a trademark of Rex Medical, LP used
under license by Angiotech. CONTACT: Angiotech Contact: Deirdre
Neary, Angiotech Pharmaceuticals, Inc., (604) 222-7056, DATASOURCE:
Angiotech Pharmaceuticals, Inc. CONTACT: Angiotech Contact: Deirdre
Neary, Angiotech Pharmaceuticals, Inc., (604) 222-7056,
Copyright
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jul 2023 bis Jul 2024